Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.

<h4>Background</h4>Progranulin (PGRN) is considered to play an important role in breast cancer tumorigenesis and in inhibiting tamoxifen-induced apoptosis. We aimed to determine whether PGRN levels are associated with breast cancer recurrence after curative surgery.<h4>Methodology/...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dong Hoe Koo, Cheol-Young Park, Eun Sook Lee, Jungsil Ro, Sang Woo Oh
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/824e5f1a718d4d0ebddfc12001a0248b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:824e5f1a718d4d0ebddfc12001a0248b
record_format	dspace
spelling	oai:doaj.org-article:824e5f1a718d4d0ebddfc12001a0248b2021-11-18T07:14:24ZProgranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.1932-620310.1371/journal.pone.0039880https://doaj.org/article/824e5f1a718d4d0ebddfc12001a0248b2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22761921/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Progranulin (PGRN) is considered to play an important role in breast cancer tumorigenesis and in inhibiting tamoxifen-induced apoptosis. We aimed to determine whether PGRN levels are associated with breast cancer recurrence after curative surgery.<h4>Methodology/principal findings</h4>We evaluated the associations between preoperative serum PGRN levels and breast cancer recurrence in a cohort of 697 newly diagnosed breast cancer patients who underwent curative surgery between April 2001 and December 2004. The mean age ± standard deviation (SD) was 46 ± 9.8 years, and all patients with hormone receptor (HR)-positive tumors received adjuvant tamoxifen therapy. At a median follow-up of 62.2 months (range, 2.9-98.2), 89 patients (12.8%) had experienced a recurrence and 51 patients (7.3%) had died. In the HR-positive group, serum PGRN levels were associated with recurrence according to the log-rank test for trend (p for trend = 0.049). There was no association between PGRN levels and recurrence in the HR-negative group (p for trend = 0.658). Adjusted hazard ratios, including possible confounders, revealed a linear relationship between serum PGRN levels and recurrence in the HR-positive group (p for trend = 0.049), and this association was further strengthened after excluding patients who had no lymph node metastasis (p for trend = 0.038).<h4>Conclusions/significance</h4>Serum PGRN levels were clinically significant for predicting recurrence in patients with HR-positive breast cancer during adjuvant tamoxifen therapy.Dong Hoe KooCheol-Young ParkEun Sook LeeJungsil RoSang Woo OhPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 6, p e39880 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Dong Hoe Koo Cheol-Young Park Eun Sook Lee Jungsil Ro Sang Woo Oh Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.
description	<h4>Background</h4>Progranulin (PGRN) is considered to play an important role in breast cancer tumorigenesis and in inhibiting tamoxifen-induced apoptosis. We aimed to determine whether PGRN levels are associated with breast cancer recurrence after curative surgery.<h4>Methodology/principal findings</h4>We evaluated the associations between preoperative serum PGRN levels and breast cancer recurrence in a cohort of 697 newly diagnosed breast cancer patients who underwent curative surgery between April 2001 and December 2004. The mean age ± standard deviation (SD) was 46 ± 9.8 years, and all patients with hormone receptor (HR)-positive tumors received adjuvant tamoxifen therapy. At a median follow-up of 62.2 months (range, 2.9-98.2), 89 patients (12.8%) had experienced a recurrence and 51 patients (7.3%) had died. In the HR-positive group, serum PGRN levels were associated with recurrence according to the log-rank test for trend (p for trend = 0.049). There was no association between PGRN levels and recurrence in the HR-negative group (p for trend = 0.658). Adjusted hazard ratios, including possible confounders, revealed a linear relationship between serum PGRN levels and recurrence in the HR-positive group (p for trend = 0.049), and this association was further strengthened after excluding patients who had no lymph node metastasis (p for trend = 0.038).<h4>Conclusions/significance</h4>Serum PGRN levels were clinically significant for predicting recurrence in patients with HR-positive breast cancer during adjuvant tamoxifen therapy.
format	article
author	Dong Hoe Koo Cheol-Young Park Eun Sook Lee Jungsil Ro Sang Woo Oh
author_facet	Dong Hoe Koo Cheol-Young Park Eun Sook Lee Jungsil Ro Sang Woo Oh
author_sort	Dong Hoe Koo
title	Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.
title_short	Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.
title_full	Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.
title_fullStr	Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.
title_full_unstemmed	Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.
title_sort	progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/824e5f1a718d4d0ebddfc12001a0248b
work_keys_str_mv	AT donghoekoo progranulinasaprognosticbiomarkerforbreastcancerrecurrenceinpatientswhohadhormonereceptorpositivetumorsacohortstudy AT cheolyoungpark progranulinasaprognosticbiomarkerforbreastcancerrecurrenceinpatientswhohadhormonereceptorpositivetumorsacohortstudy AT eunsooklee progranulinasaprognosticbiomarkerforbreastcancerrecurrenceinpatientswhohadhormonereceptorpositivetumorsacohortstudy AT jungsilro progranulinasaprognosticbiomarkerforbreastcancerrecurrenceinpatientswhohadhormonereceptorpositivetumorsacohortstudy AT sangwoooh progranulinasaprognosticbiomarkerforbreastcancerrecurrenceinpatientswhohadhormonereceptorpositivetumorsacohortstudy
_version_	1718423736582930432

Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.

Ejemplares similares